H.C. Wainwright analyst Edward White maintained a Buy rating on G1 Therapeutics Inc (GTHX) today and set a price target of $75. The company’s shares closed yesterday at $43.20.
White noted:
“We base our $75 price target on probability-adjusted revenue forecasts for trilaciclib in first line SCLC, second and third line SCLC, and metastatic TNB cancer plus lerociclib in ER+, HER2- breast cancer and EGFR mutant NSCLC. We use the net present value of our revenue forecast through 2026, apply a 50% and 40% POS for trilaciclib and lerociclib, respectively, a 3x price/sales multiple, and a $2.42/share value for the early stage pipeline that includes trilaciclib and lerociclib in other indications, and G1T48, which if approved will compete with Faslodex, a drug that recorded sales of $941M in 2017.”
According to TipRanks.com, White is a 5-star analyst with an average return of 15.2% and a 46.1% success rate. White covers the Healthcare sector, focusing on stocks such as Syndax Pharmaceuticals Inc, Spectrum Pharmaceuticals, and Synthetic Biologics Inc.
G1 Therapeutics Inc has an analyst consensus of Strong Buy, with a price target consensus of $77.
See today’s analyst top recommended stocks >>
The company has a one-year high of $69.57 and a one-year low of $18.04. Currently, G1 Therapeutics Inc has an average volume of 322K.
Based on the recent corporate insider activity of 55 insiders, corporate insider sentiment is negative on the stock.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
G1 Therapeutics, Inc. develops drugs for cancer treatment. It is a clinical-stage pharmaceutical company that focuses on the discovery and development of novel therapies to address significant unmet needs in oncology. The company was founded by Kwok-Kin Wong and Norman E. Sharpless on May 19, 2008 and is headquartered in Research Triangle Park, NC.
